microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective.

Cells 2021 Jan 9;10(1). Epub 2021 Jan 9.

Department Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.

Pathogenic processes underlying Alzheimer's disease (AD) affect synaptic function from initial asymptomatic stages, long time before the onset of cognitive decline and neurodegeneration. Therefore, reliable biomarkers enabling early AD diagnosis and prognosis are needed to maximize the time window for therapeutic interventions. MicroRNAs (miRNAs) have recently emerged as promising cost-effective and non-invasive biomarkers for AD, since they can be readily detected in different biofluids, including cerebrospinal fluid (CSF) and blood. Moreover, a growing body of evidence indicates that miRNAs regulate synaptic homeostasis and plasticity processes, suggesting that they may be involved in early synaptic dysfunction during AD. Here, we review the current literature supporting a role of miRNAs during early synaptic deficits in AD, including recent studies evaluating their potential as AD biomarkers. Besides targeting genes related to Aβ and tau metabolism, several miRNAs also regulate synaptic-related proteins and transcription factors implicated in early synaptic deficits during AD. Furthermore, individual miRNAs and molecular signatures have been found to distinguish between prodromal AD and healthy controls. Overall, these studies highlight the relevance of considering synaptic-related miRNAs as potential biomarkers of early AD stages. However, further validation studies in large cohorts, including longitudinal studies, as well as implementation of standardized protocols, are needed to establish miRNA-based biomarkers as reliable diagnostic and prognostic tools.

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells10010113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827653PMC
January 2021
Get 20% Off Journals at LWW.com

Similar Publications

A GABA receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.

Neurobiol Dis 2021 Feb 20:105304. Epub 2021 Feb 20.

Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy. Electronic address:

CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a severe neurodevelopmental encephalopathy characterized by early-onset epilepsy and intellectual disability. Studies in mouse models have linked CDKL5 deficiency to defects in neuronal maturation and synaptic plasticity, and disruption of the excitatory/inhibitory balance. Interestingly, increased density of both GABAergic synaptic terminals and parvalbumin inhibitory interneurons was recently observed in the primary visual cortex of Cdkl5 knockout (KO) mice, suggesting that excessive GABAergic transmission might contribute to the visual deficits characteristic of CDD. Read More

View Article and Full-Text PDF
February 2021

Retinoid X Receptor activation promotes re-myelination in a very old triple transgenic mouse model of Alzheimer's disease.

Neurosci Lett 2021 Feb 20:135764. Epub 2021 Feb 20.

Grupos de Muerte Celular, Instituto de Genética, Universidad Nacional de Colombia, Colombia; Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Colombia. Electronic address:

Alzheimer's disease (AD) is the main cause of dementia in the world. Studies of human AD brains show abnormalities in the white matter and reduction of myelin and oligodendrocyte markers. It has been proposed that oligodendrocyte progenitor cells (OPCs) present in the adult brain are a potential source for re-myelination, through proliferation and differentiation into mature oligodendrocytes. Read More

View Article and Full-Text PDF
February 2021

Overexpression of protein kinase Mζ in the hippocampal dentate gyrus rescues amyloid-β-induced synaptic dysfunction within entorhinal-hippocampal circuit.

Neurobiol Aging 2021 Jan 31;101:160-171. Epub 2021 Jan 31.

Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran. Electronic address:

Entorhinal cortex (EC) is one of the first cerebral regions affected in the early phase of Alzheimer's disease (AD). Soluble forms of amyloid beta (Aβ) impair synaptic transmission in experimental AD models. Protein kinase Mζ (PKMζ) is an atypical persistently active protein kinase C, known to maintain long term synaptic plasticity and memory, but its role in AD has not yet been described. Read More

View Article and Full-Text PDF
January 2021

Brain glycogen metabolism: A possible link between sleep disturbances, headache and depression.

Sleep Med Rev 2021 Jan 29;59:101449. Epub 2021 Jan 29.

Hacettepe University, Institute of Neurological Sciences and Psychiatry, Ankara, Turkey. Electronic address:

The functions of sleep and its links with neuropsychiatric diseases have long been questioned. Among the numerous hypotheses on sleep function, early studies proposed that sleep helps to replenish glycogen stores consumed during waking. Later studies found increased brain glycogen after sleep deprivation, leading to "glycogenetic" hypothesis, which states that there is a parallel increase in synthesis and utilization of glycogen during wakefulness, whereas decrease in the excitatory transmission creates an imbalance causing accumulation of glycogen during sleep. Read More

View Article and Full-Text PDF
January 2021

Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice.

J Psychiatr Res 2021 Feb 14;136:204-216. Epub 2021 Feb 14.

College of Medicine, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials Ministry of Education, Nankai University, Tianjin, 300071, China. Electronic address:

Background: As an increasing population of Alzheimer's disease (AD) patients year by year, which is a serious threat to human health, an effective approach to prevent and treat AD is required. Biomarker changes relevant to β-amyloid (Aβ) 20 years or more in advance of cognitive impairment, so early intervention is a feasible idea for AD therapy. Repetitive transcranial magnetic stimulation (rTMS) as a non-invasive technique offers the possibility of early intervention. Read More

View Article and Full-Text PDF
February 2021